Home › Burkitt Lymphoma › California

Burkitt Lymphoma clinical trials in California

21 studies for Burkitt Lymphoma are looking for participants at sites in California.

Cities in California

Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia

Research Site, Duarte

RecruitingPhase 1/2

Ages 12 and older · All sexes · Updated Nov 13, 2026 · NCT07109219

A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)

Children's Hospital Los Angeles, Los Angeles
Lucile Packard Children's Hospital, Stanford University, Palo Alto

RecruitingPhase 1

Ages 0 to 18 · All sexes · Updated Nov 13, 2026 · NCT06173518

Genetically Engineered Cells (BAFFR-CAR T Cells) for the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia and B-cell Lymphoblastic Lymphoma

City of Hope Medical Center, Duarte
City of Hope at Irvine Lennar, Irvine

RecruitingPhase 1

Ages 18 and older · All sexes · Updated Nov 13, 2026 · NCT07758673

Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

City of Hope Comprehensive Cancer Center, Duarte
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine
UC San Diego Moores Cancer Center, La Jolla
and 1 more

RecruitingPhase 2

Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT03739814

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Kaiser Permanente Downey Medical Center, Downey
Kaiser Permanente-Fontana, Fontana
Loma Linda University Medical Center, Loma Linda
and 13 more

RecruitingPhase 2

Ages 1 to 30 · All sexes · Updated Nov 12, 2026 · NCT04546399

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

Kaiser Permanente-Deer Valley Medical Center, Antioch
Community Cancer Institute, Clovis
UC Irvine Health Cancer Center-Newport, Costa Mesa
and 26 more

RecruitingPhase 3

Ages 18 to 39 · All sexes · Updated Nov 3, 2026 · NCT03150693

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

Children's Hospital Los Angeles ( Site 1006), Los Angeles

RecruitingPhase 1/2

6 Months – 25 Years · All sexes · Updated Oct 30, 2026 · NCT06395103

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

Loma Linda University Medical Center, Loma Linda
Miller Children's and Women's Hospital Long Beach, Long Beach
UCSF Benioff Children's Hospital Oakland, Oakland
and 4 more

RecruitingPhase 2

365 Days · All sexes · Updated Oct 27, 2026 · NCT06317662

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

Kaiser Permanente Downey Medical Center, Downey
Loma Linda University Medical Center, Loma Linda
Miller Children's and Women's Hospital Long Beach, Long Beach
and 9 more

RecruitingPhase 2

366 Days – 46 Years · All sexes · Updated Oct 27, 2026 · NCT06124157

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

City of Hope, Duarte
Valkyrie Clinical Trials, Los Angeles

RecruitingPhase 1/2

Ages 13 to 90 · All sexes · Updated Oct 26, 2026 · NCT06533579

Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma

University of California, San Francisco, San Francisco

RecruitingPhase 1

Ages 18 and older · All sexes · Updated Oct 26, 2026 · NCT04545762

Recombinant Erwinia Asparaginase and Venetoclax in Combination With Blinatumomab for the Treatment of Relapsed or Refractory CD19 Positive B-cell Acute Lymphoblastic Leukemia

City of Hope Medical Center, Duarte

RecruitingPhase 1

Ages 12 to 55 · All sexes · Updated Oct 16, 2026 · NCT07133997

Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies

UC Irvine, Orange

RecruitingPhase 3

Ages 18 and older · All sexes · Updated Oct 14, 2026 · NCT07648264

Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene

UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine
UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange

RecruitingPhase 1/2

Ages 18 and older · All sexes · Updated Oct 14, 2026 · NCT07069699

AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia

Research Site, Duarte
Research Site, Los Angeles
Research Site, Palo Alto

RecruitingPhase 1/2

Ages 12 and older · All sexes · Updated Oct 13, 2026 · NCT06137118

Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

City of Hope Medical Center, Duarte
City of Hope at Irvine Lennar, Irvine
UC San Diego Moores Cancer Center, La Jolla
and 1 more

RecruitingPhase 2

Ages 18 to 54 · All sexes · Updated Oct 13, 2026 · NCT06918431

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

Kaiser Permanente Downey Medical Center, Downey
City of Hope Comprehensive Cancer Center, Duarte
Loma Linda University Medical Center, Loma Linda
and 14 more

RecruitingPhase 3

365 Days – 25 Years · All sexes · Updated Aug 25, 2026 · NCT03959085

Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL

Children's Hospital Los Angeles, Los Angeles
Children's Hospital Orange County, Orange
UCSF School of Medicine, San Francisco

RecruitingPhase 2

Ages 7 to 25 · All sexes · Updated Aug 19, 2026 · NCT05082519

AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas

Stanford University, Palo Alto

RecruitingPhase 1

Ages 18 and older · All sexes · Updated Aug 12, 2026 · NCT06340737

Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL

City of Hope, Duarte

RecruitingPhase 1

Ages 18 and older · All sexes · Updated Nov 5, 2025 · NCT04260022

The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL

City of Hope, Duarte
Children's Hospital Los Angeles, Los Angeles
UCLA Mattel Children's Hospital, Los Angeles
and 2 more

RecruitingPhase 2

Ages 1 to 25 · All sexes · Updated May 4, 2025 · NCT03509961

From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.